Anthem Biosciences lists with 27% premium on the BSE
Anthem Biosciences has debuted at Rs 723.10 on the BSE, up by 153.1 points or 26.86% from its issue price of Rs 570.00.
The scrip is currently trading at Rs. 724.75, up by 154.75 points or 27.15% from its issue price.
It has touched a high and low of Rs. 746.70 and Rs. 723.05 respectively. So far 30.51 lakh shares were traded on the counter.
The offering, which was open for subscription between July 14, 2025 and July 16, 2025 was subscribed 67.42 times. The issue price was fixed at Rs 570 per share i.e. at upper end of price band of Rs 540-570 apiece.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem's business also manufactures and sale of specialty ingredients. It also manufactures and sells complex specialised fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, and biosimilars.
